Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

被引：0

作者：

Harada, Takeshi ^{[1
]}

Oda, Asuka ^{[1
]}

Ohguchi, Hiroto ^{[2
]}

Grondin, Yohann ^{[3
]}

Tenshin, Hirofumi ^{[4
]}

Hiasa, Masahiro ^{[4
]}

Teramachi, Jumpei ^{[5
]}

Oura, Masahiro ^{[1
]}

Sogabe, Kimiko ^{[1
]}

Fujii, Shiro ^{[1
]}

Nakamura, Shingen ^{[1
]}

Miki, Hirokazu ^{[6
]}

Kagawa, Kumiko ^{[1
]}

Ozaki, Shuji ^{[7
]}

Hideshima, Teru ^{[8
]}

Anderson, Kenneth C. ^{[8
]}

Abe, Masahiro ^{[1
]}

机构：

[1] Tokushima Univ, Inst Biomed Sci, Dept Hematol Endocrinol & Metab, Grad Sch, Tokushima, Japan

[2] Kumamoto Univ, Div Dis Epigenet, IRDA, Kumamoto, Japan

[3] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA USA

[4] Tokushima Univ, Inst Biomed Sci, Dept Orthodont & Dentofacial Orthoped, Grad Sch, Tokushima, Japan

[5] Tokushima Univ, Inst Biomed Sci, Dept Tissue Regenerat, Grad Sch, Tokushima, Japan

[6] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Japan

[7] Tokushima Prefectural Cent Hosp, Dept Hematol, Tokushima, Japan

[8] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1182/blood-2019-127679

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3111

引用

页数：3